Pre-made Mosunetuzumab benchmark antibody ( Bispecific mAb, anti-CD3E;MS4A1/CD20 therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-356-1mg	1mg	Inquiry
GMP-Bios-ab-356-10mg	10mg	Inquiry
GMP-Bios-ab-356-100mg	100mg	Inquiry
GMP-Bios-ab-356-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Mosunetuzumab biosimilar, Bispecific mAb, Anti-CD3E;MS4A1/CD20 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;B1/Bp35/CVID5/FMC7/LEU-16/S7 therapeutic antibody
INN Name	Mosunetuzumab
Target	CD3E;CD20
Format	Bispecific mAb
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;4k7p:YX
Year Proposed	2017
Year Recommended	2018
Companies	Genentech
Conditions Approved	na
Conditions Active	Diffuse large B cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma;Follicular lymphoma
Conditions Discontinued	na
Development Tech	na